Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador [Yahoo! Finance]
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS)
Last fresenius medical care ag american depositary shares (each representing 1/2 of an ordinary share) earnings: 7/31 04:03 pm
Check Earnings Report
US:NYSE Investor Relations:
freseniusmedicalcare.com/en/investors/investors-overview
Company Research
Source: Yahoo! Finance
Transactions further reduce the Company's clinic footprint in Latin America , following the exit from Argentina at the end of 2023 Expected to close throughout 2024 Proceeds to be used to reduce debt BAD HOMBURG, Germany March 5, 2024 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil Colombia Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million . Subject to regulatory approvals in Brazil Colombia and Ecuador , the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024. "We continue to move at pace in optimizing our portfolio, to reduce complexity and improve profitability. This is a key element of our transformational journey," said Helen Giza , CEO for Fresenius Medical Care AG. "I also wanted to take a moment t
Show less
Read more
Impact Snapshot
Event Time:
FMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FMS alerts
High impacting Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) news events
Weekly update
A roundup of the hottest topics
FMS
News
- Global Hemodialysis and Peritoneal Dialysis Research Report 2024-2029: Increasing Growth Opportunities in Emerging Economies, Rising Number of Dialysis Centers, Growing Preference for Home Care [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care AG (NYSE: FMS) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care AG (NYSE: FMS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S. [Yahoo! Finance]Yahoo! Finance
FMS
Earnings
- 8/3/23 - In-Line
FMS
Sec Filings
- 5/3/24 - Form 6-K
- 3/28/24 - Form 6-K
- 3/13/24 - Form 6-K
- FMS's page on the SEC website